Q-omics provides the consensus-scored GLT8D2 profile across patient tissues and cancer cell-line models. GLT8D2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GLT8D2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, GLT8D2 RNA expression shows 20,799 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, THCA, and BRCA as cancer lineages where GLT8D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLT8D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLT8D2 survival associations across molecular data types. GLT8D2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLT8D2 RNA expression–survival associations across cancer types. High GLT8D2 expression shows unfavorable associations in KIRP, MESO, STAD, CESC, BLCA and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GLT8D2 RNA expression.
This table summarizes GLT8D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GLT8D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLT8D2 shows lower tumor expression in THCA, KICH, UCEC, KIRC and BLCA and higher tumor expression in HNSC. The THCA box plot shows higher GLT8D2 RNA expression in normal versus tumor tissue (log2 FC = −3.122, t-test p < 0.001).
This table shows molecular features associated with GLT8D2 in patient tissues and cancer cell lines. In patient samples, GLT8D2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GLT8D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
